CDK4 and non-small cell lung carcinoma: In conclusion, we demonstrate for the first time that the CDK4/6 inhibitor PD 0332991 is a promising drug in the treatment of NSCLC patients with EGFR-TKI drug resistance by blocking pRb-mediated cell cycle progression.